1. SongI ChenS LouY et al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572 a next generation integrase inhibitor (INI) in HIV‐1 infected patients. In: Posters of the Fifth IAS Conference on HIV Pathogenesis Treatment and Prevention Cape Town South Africa.2009. Poster WEPEB250. International AIDS Society Geneva Switzerland.
2. Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
3. ArribasJ LazzarinA RaffiF et al. Once‐daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16‐week analysis from SPRING‐1 (ING112276). In: Abstracts of the Eighteenth International AIDS Conference Vienna Austria 2010. Abstract THLBB205. International AIDS Society Geneva Switzerland.
4. UnderwoodM JohnsB SatoA FujiwaraT SpreenW. S/GS K1349572: a next generation integrase inhibitor with activity against integrase inhibitor‐resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. In: Posters of the Fifth IAS Conference on HIV Pathogenesis Treatment and Prevention Cape Town South Africa.2009. Poster WEPEA098. International AIDS Society Geneva Switzerland.
5. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study